Allschwil, Switzerland, April 24, 2024
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage
biopharmaceutical company committed to meeting the needs of patients with severe
bacterial and fungal infections, reported that shareholders approved all
proposals of the board of directors at today's annual general meeting (AGM) for
the financial year 2023.
At the AGM, the shareholders approved the annual report, the financial
statements and the consolidated financial statements for the financial year
2023. They also endorsed carrying forward the accumulated deficit and approved
the discharge of the members of the board of directors and the management
committee.
Mr. Domenico Scala was re-elected as chairman and Mr. Leonard Kruimer, Dr.
Martin Nicklasson, Dr. Nicole Onetto, Dr. Carole Sable and Dr. Thomas Werner
were re-elected as members of the board of directors. In addition,
Dr. Nicklasson, Dr. Onetto and Dr. Werner were re-elected to the compensation
committee. The term of all board members lasts until the AGM 2025.
The shareholders also approved the proposed maximum aggregate amount of
compensation for the board of directors for the period from the AGM 2024 to the
AGM 2025, and the maximum aggregate amount of total compensation (fixed and
variable) for the management committee for the financial year 2025. In a non-
binding advisory vote, the shareholders endorsed the compensation report for the
financial year 2023.
Finally, the shareholders re-elected Dr. Caroline Cron as independent proxy
until the end of the next AGM and re-elected PricewaterhouseCoopers Ltd, Basel,
as auditors for the financial year 2024.
At the AGM, 35.9% of the share capital, equivalent to 59.7% of the shares
entitled to vote, was represented. In total, 69.9% of the share capital is
currently registered in Basilea's share register.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and
headquartered in Switzerland. We are committed to discovering, developing and
commercializing innovative drugs to meet the needs of patients with severe
bacterial and fungal infections. We have successfully launched two hospital
brands, Cresemba for the treatment of invasive fungal infections and Zevtera for
the treatment of bacterial infections. In addition, we have preclinical and
clinical anti-infective assets in our portfolio. Basilea is listed on the SIX
Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements, such as "believe", "assume", "expect", "forecast", "project", "may",
"could", "might", "will" or similar expressions concerning Basilea Pharmaceutica
Ltd, Allschwil and its business, including with respect to the progress, timing
and completion of research, development and clinical studies for product
candidates. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results, financial
condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Basilea Pharmaceutica
Ltd, Allschwil is providing this communication as of this date and does not
undertake to update any forward-looking statements contained herein as a result
of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

 Phone  +41 61 606 1102
        media_relations@basilea.com (mailto:media_relations@basilea.com)

E-mail investor_relations@basilea.com (mailto:investor_relations@basilea.com)
This press release can be downloaded from www.basilea.com
(https://www.basilea.com/).
Press release (PDF) (https://ml-eu.globenewswire.com/Resource/Download/3699290d-
8bfd-44ff-bbc8-23e879b7a9b8)
Â